These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25823632)

  • 1. Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013.
    Turner L; Kruszewski SP; Alexander GC
    Am J Addict; 2015 Jan; 24(1):24-9. PubMed ID: 25823632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rise and regional disparities in buprenorphine utilization in the United States.
    Pashmineh Azar AR; Cruz-Mullane A; Podd JC; Lam WS; Kaleem SH; Lockard LB; Mandel MR; Chung DY; Simoyan OM; Davis CS; Nichols SD; McCall KL; Piper BJ
    Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):708-715. PubMed ID: 32173955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R; Appajosyula S; Deximo C
    Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
    Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H
    Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Office-based buprenorphine treatment for opioid-dependent patients.
    McCance-Katz EF
    Harv Rev Psychiatry; 2004; 12(6):321-38. PubMed ID: 15764468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians.
    Arfken CL; Johanson CE; di Menza S; Schuster CR
    J Subst Abuse Treat; 2010 Sep; 39(2):96-104. PubMed ID: 20598829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. US physicians' decision-making during buprenorphine-naloxone treatment: Conjoint analyses of dose and office visit adjustments based on patient progress.
    Knudsen HK; Lofwall MR; Lin LA; Walsh SL; Studts JL
    Drug Alcohol Depend; 2019 Nov; 204():107490. PubMed ID: 31518885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Group-based treatment of opioid use disorder with buprenorphine: A systematic review.
    Sokol R; LaVertu AE; Morrill D; Albanese C; Schuman-Olivier Z
    J Subst Abuse Treat; 2018 Jan; 84():78-87. PubMed ID: 29195596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine for opioid dependence.
    Ling W
    Expert Rev Neurother; 2009 May; 9(5):609-16. PubMed ID: 19402772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
    Gunderson EW; Hjelmström P; Sumner M;
    Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.
    Mokri A; Chawarski MC; Taherinakhost H; Schottenfeld RS
    Addiction; 2016 May; 111(5):874-82. PubMed ID: 26639678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of buprenorphine/naloxone prescribing: an analysis of claims data from Massachusetts.
    Paulsen R; Modestino AS; Hasan MM; Noor-E-Alam M; Young LD; Young GJ
    Am J Drug Alcohol Abuse; 2020; 46(2):216-223. PubMed ID: 31825718
    [No Abstract]   [Full Text] [Related]  

  • 15. Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.
    Kraus ML; Alford DP; Kotz MM; Levounis P; Mandell TW; Meyer M; Salsitz EA; Wetterau N; Wyatt SA;
    J Addict Med; 2011 Dec; 5(4):254-63. PubMed ID: 22042215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine for office-based practice: consensus conference overview.
    Kosten TR; Fiellin DA;
    Am J Addict; 2004; 13 Suppl 1():S1-7. PubMed ID: 15204671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Training in Buprenorphine and Office-Based Opioid Treatment: A Survey of Psychiatry Residency Training Programs.
    Suzuki J; Ellison TV; Connery HS; Surber C; Renner JA
    Acad Psychiatry; 2016 Jun; 40(3):498-502. PubMed ID: 26017618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States.
    Asche CV; Clay E; Kharitonova E; Zah V; Ruby J; Aballéa S
    J Med Econ; 2015; 18(8):600-11. PubMed ID: 25851505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing opioid addiction with buprenorphine.
    Donaher PA; Welsh C
    Am Fam Physician; 2006 May; 73(9):1573-8. PubMed ID: 16719249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.